DDInter500 DDInter172
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides. Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women. It further received additional indication approval to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Durvalumab
Denosumab {u} may lead to a major life threatening interaction when taken with {v} Etelcalcetide
Denosumab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Denosumab may lead to a major life threatening interaction when taken with Etelcalcetide
Denosumab may lead to a major life threatening interaction when taken with Cladribine